Mirum Pharmaceuticals, Inc. business relationships
Companies named in Mirum Pharmaceuticals, Inc.’s 10-K filed 2026-02-25, and public companies whose annual reports name Mirum Pharmaceuticals, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 67 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Mirum Pharmaceuticals, Inc.’s annual report 11
“Upon commercialization of any product utilizing the licensed product, the Company is required to pay to Pfizer a low single-digit royalty on net sales of product sold by the Company, its affiliates or sublicensees.” SEC filing
“We expect that total product sales of our approved medicines will continue to increase on an annual basis; however, due to large periodic orders from Takeda and our distributors, our product revenue may experience quarterly fluctuations.” SEC filing
“Under the terms of the license agreement, Novartis is entitled to receive up to $8.0 million in development milestones and up to $27.0 million in commercial milestones.” SEC filing
“For example, certain trade secrets related to maralixibat are licensed from Pfizer, and patents, patent applications and trade secrets related to volixibat are licensed from Sanofi.” SEC filing
“Licensing Agreement with Takeda” SEC filing
“Upon commercialization of any product utilizing the Sanofi Technology, we will be required to pay to Sanofi tiered royalties in the mid to high single-digit range based upon net sales of licensed products sold by us and our affiliates and sublicensees in a calendar year, subject to adjustments in ce...” SEC filing
“For example, certain trade secrets related to maralixibat are licensed from Pfizer, and patents, patent applications and trade secrets related to volixibat are licensed from Sanofi.” SEC filing
“Manufacturing and License Agreement with Lonza Ltd.” SEC filing
“License Agreement with Enthorin Therapeutics, LLC” SEC filing
“License Agreement with Enthorin Therapeutics, LLC and Dart Neuroscience LLC” SEC filing
“License Agreement by and between Lumena Pharmaceuticals, Inc. and Pfizer Inc., dated June 1, 2012 (filed as Exhibit 10.17 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-232251), filed with the SEC on June 21, 2019, and incorporated by reference herein).” SEC filing
Companies whose annual reports name Mirum Pharmaceuticals, Inc. 1
“| Mirum Pharmaceuticals | | U.S. | | Exclusive licensing agreement for the development and commercialization of LIVMARLI (maralixibat, TAK-625) in Japan for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). |” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.